A trial with 19 imatinib-treated patients with CML in the first chronic phase were vaccinated with BCR-ABL peptides spanning the e14a2 fusion junction, and 14 of the 19 patients developed T cell responses to BCR-ABL peptides. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.